|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 47/48 | (2018.01) |
| C07D 489/04 | (2006.01) | ||
| A61P 39/00 | (2006.01) |
| (11) | Number of the document | 2621496 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11829686.2 |
| Date of filing the European patent application | 2011-09-29 | |
| (97) | Date of publication of the European application | 2013-08-07 |
| (45) | Date of publication and mention of the grant of the patent | 2015-12-16 |
| (46) | Date of publication of the claims translation | 2016-01-25 |
| (86) | Number | PCT/SE2011/051161 |
| Date | 2011-09-29 |
| (87) | Number | WO 2012/044243 |
| Date | 2012-04-05 |
| (30) | Number | Date | Country code |
| 388501 P | 2010-09-30 | US |
| (72) |
ÅSLUND, Bengt Leonard , SE
AURELL, Carl-Johan , SE
BOHLIN, Martin Hans , SE
SEBHATU, Tesfai , SE
YMÉN, Bo Ingvar , SE
HEALY, Eric Thomas , US
JENSEN, David Richard , US
JONAITIS, David Thomas , US
PARENT, Stephan , US
LECHUGA-BALLESTEROS, David , US
|
| (73) |
Nektar Therapeutics,
455 Mission Bay Boulevard South, Suite 100, San Francisco, CA 94185,
US
Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, DE |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kristalinis naloksolo-PEG konjugatas |
| CRYSTALLINE NALOXOL-PEG CONJUGATE |
| Payment date | Validity (years) | Amount | |
| 2024-08-23 | 14 | 289.00 EUR |
| 2025-09-29 |